Erica J. Rogers Sells 11,000 Shares of Silk Road Medical, Inc (NASDAQ:SILK) Stock

Silk Road Medical, Inc (NASDAQ:SILK) CEO Erica J. Rogers sold 11,000 shares of Silk Road Medical stock in a transaction on Monday, October 11th. The stock was sold at an average price of $55.73, for a total transaction of $613,030.00. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Erica J. Rogers also recently made the following trade(s):

  • On Monday, September 13th, Erica J. Rogers sold 11,000 shares of Silk Road Medical stock. The shares were sold at an average price of $57.32, for a total transaction of $630,520.00.

SILK opened at $53.97 on Thursday. Silk Road Medical, Inc has a fifty-two week low of $43.11 and a fifty-two week high of $75.80. The company has a debt-to-equity ratio of 0.51, a quick ratio of 8.75 and a current ratio of 9.51. The company has a fifty day moving average of $55.71 and a two-hundred day moving average of $51.86. The stock has a market capitalization of $1.87 billion, a price-to-earnings ratio of -38.01 and a beta of 1.51.

Silk Road Medical (NASDAQ:SILK) last released its quarterly earnings data on Thursday, July 29th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.06. Silk Road Medical had a negative net margin of 53.85% and a negative return on equity of 45.52%. The company had revenue of $26.46 million during the quarter, compared to analysts’ expectations of $25.33 million. On average, equities research analysts forecast that Silk Road Medical, Inc will post -1.24 earnings per share for the current year.

A number of research analysts recently issued reports on the stock. Piper Sandler decreased their target price on shares of Silk Road Medical from $58.00 to $55.00 and set a “neutral” rating for the company in a research report on Friday, July 30th. Zacks Investment Research upgraded shares of Silk Road Medical from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a research report on Thursday, September 30th. SVB Leerink restated an “outperform” rating on shares of Silk Road Medical in a research report on Tuesday, July 20th. Finally, Citigroup downgraded shares of Silk Road Medical from a “neutral” rating to a “sell” rating and set a $50.00 target price for the company. in a research report on Friday, October 1st.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alliancebernstein L.P. increased its stake in shares of Silk Road Medical by 4.9% during the second quarter. Alliancebernstein L.P. now owns 2,403,291 shares of the company’s stock worth $115,022,000 after purchasing an additional 112,837 shares in the last quarter. TimesSquare Capital Management LLC increased its stake in shares of Silk Road Medical by 4.3% during the second quarter. TimesSquare Capital Management LLC now owns 954,750 shares of the company’s stock worth $45,694,000 after purchasing an additional 39,250 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Silk Road Medical by 12.9% during the first quarter. Thrivent Financial for Lutherans now owns 396,822 shares of the company’s stock worth $20,099,000 after purchasing an additional 45,319 shares in the last quarter. Voloridge Investment Management LLC increased its stake in shares of Silk Road Medical by 26.1% during the first quarter. Voloridge Investment Management LLC now owns 74,845 shares of the company’s stock worth $3,791,000 after purchasing an additional 15,490 shares in the last quarter. Finally, Royal Bank of Canada increased its stake in shares of Silk Road Medical by 27.5% during the first quarter. Royal Bank of Canada now owns 5,299 shares of the company’s stock worth $268,000 after purchasing an additional 1,144 shares in the last quarter.

About Silk Road Medical

Silk Road Medical, Inc develops and manufactures medical devices to treat neurovascular diseases. Its products include ENROUTE transcarotid neuroprotection system, ENROUTE transcarotid stent system, and ENROUTE transcarotid peripheral access kit. The company was founded by Tony M. Chou and Michi Garrison on March 21, 2007 and is headquartered in Sunnyvale, CA.

Featured Article: How can investors benefit from after-hours trading?

Insider Buying and Selling by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with MarketBeat.com's FREE daily email newsletter.